KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Amneal Pharmaceuticals (AMRX) EPS (Weighted Average and Diluted) (2018 - 2026)

Amneal Pharmaceuticals has reported EPS (Weighted Average and Diluted) over the past 8 years, most recently at $0.11 for Q4 2025.

  • For Q4 2025, EPS (Weighted Average and Diluted) rose 210.0% year-over-year to $0.11; the TTM value through Dec 2025 reached $0.23, up 160.53%, while the annual FY2025 figure was $0.22, 157.89% up from the prior year.
  • EPS (Weighted Average and Diluted) for Q4 2025 was $0.11 at Amneal Pharmaceuticals, up from $0.01 in the prior quarter.
  • Over five years, EPS (Weighted Average and Diluted) peaked at $0.11 in Q4 2025 and troughed at -$0.8 in Q2 2022.
  • A 5-year average of -$0.07 and a median of $0.0 in 2022 define the central range for EPS (Weighted Average and Diluted).
  • On a YoY basis, EPS (Weighted Average and Diluted) climbed as much as 400.0% in 2023 and fell as far as 1800.0% in 2023.
  • Year by year, EPS (Weighted Average and Diluted) stood at -$0.04 in 2021, then rose by 25.0% to -$0.03 in 2022, then plummeted by 1800.0% to -$0.57 in 2023, then soared by 82.46% to -$0.1 in 2024, then soared by 210.0% to $0.11 in 2025.
  • Business Quant data shows EPS (Weighted Average and Diluted) for AMRX at $0.11 in Q4 2025, $0.01 in Q3 2025, and $0.07 in Q2 2025.